Discover
ALZN
Alzamend Neuro, Inc.
1.12
2 x 0.94
2 x 1.36
bid
ask
-
0.08
6.67%
2 @ 06:13 AM
1.06 -0.06 (5.36%)
| Ytd | -38.46% | |
| 1y | -61.64% |
1.06
day range
1.32
0.84
52 week range
3.60
| Open | 1.32 | Prev Close | 1.20 | Low | 1.06 | High | 1.32 | Mkt Cap | 4.26M |
| Vol | 2.27M | Avg Vol | 146.40K | EPS | -3.67 | P/E | N/A | Forward P/E | -0.26 |
| Beta | -0.04 | Short Ratio | 1.03 | Inst. Own | 0.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-02 | 50-d Avg | 1.14 | 200-d Avg | 1.83 | 1yr Est | 32.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-12-11 | 2024-10 | -2.38 | -0.4 | 1.98 | 83.19% |
| 2024-09-11 | 2024-07 | 0 | -1.25 | N/A | N/A |
| 2024-09-11 | 2024-07 | 0 | N/A | N/A | N/A |
| 2024-08-01 | 2024-04 | 0 | N/A | N/A | N/A |
| 2024-03-25 | 2024-01 | 0 | N/A | N/A | N/A |
| 2024-03-25 | 2024-01 | 0 | -3.8 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-16 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-11-11 | Ascendiant Capital | Upgrade | Buy | Buy |
Profile
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-04-18 | AULT MILTON C III | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2022-03-30 | GUSTAFSON MARK GARLAND | Director | 60.00K | Sale |
| 2023-02-23 | HORNE WILLIAM B | Director | 1000.00K | Conversion of Exercise of derivative security |
| 2023-04-27 | JACKMAN STEPHAN | Chief Executive Officer | 45.50K | Purchase |
| 2023-09-25 | KATZOFF DAVID J | Chief Financial Officer | 81.00K | Purchase |
| 2023-12-25 | MCGRATH LYNNE FAHEY | Director | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Susquehanna International Group, LLP | 16.60K | 19.76K | 0.31% |
| 2024-09-29 | Truist Financial Corp | 15.50K | 18.44K | 0.29% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 4.17K | 4.96K | 0.08% |
| 2024-09-29 | Blackrock Inc. | 3.97K | 4.73K | 0.07% |
| 2024-09-29 | Wells Fargo & Company | 1000 | 1.19K | 0.02% |
| 2024-09-29 | Corecap Advisors, LLC | 708.00 | 842.00 | 0.01% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Extended Market Index Fund | 7.85K | 9.35K | 0.14% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 3.85K | 4.58K | 0.07% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 2.19K | 2.60K | 0.04% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 999.00 | 1.19K | 0.02% |
| 2024-10-30 | Fidelity Total Market Index Fund | 705.00 | 838.00 | 0.01% |
Split
| Split | Date |
|---|---|
| 1 : 9 | 2025-05-12 |
| 1 : 10 | 2024-07-16 |
| 1 : 15 | 2023-10-31 |